Disitamab Vedotin (RC48) in Hormone Receptor Positive, HER2-low Metastatic Breast Cancer (the Rosy Trial)
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: HR Positive/HER2 Low Expression Metastatic Breast Cancer
Interventions: DRUG: Disitamab vedotin|OTHER: Endocrine therapy
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University